EP Patent

EP1447405A4 — QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS

Assigned to Kyowa Kirin Co Ltd · Expires 2005-01-12 · 21y expired

What this patent protects

The invention provides novel compounds which exhibit an inhibitory activity against autophosphorylation of FGF receptor family and can inhibit the proliferation of cancer cells through oral or intravenous administration, specifically compounds represented by the general formula (…

USPTO Abstract

The invention provides novel compounds which exhibit an inhibitory activity against autophosphorylation of FGF receptor family and can inhibit the proliferation of cancer cells through oral or intravenous administration, specifically compounds represented by the general formula (|) or pharmaceutically acceptable salts or solvates thereof: (|) wherein X is CH or N; Z is O or S; Q is NR10, CR11R12, carbonyl, O, S(=O)m (wherein m is 0 to 2), or urea; R1, R2 and R3 are each H, OH, halogeno, nitro, amino, alkyl, alkoxy, or the like (with the proviso that the alkyl and the alkoxy may be further substituted); R4 is H; R5, R6, R7 and R8 are each H, halogeno, alkyl, or alkoxy; and R9 is a carbocyclic or heterocyclic group which may be substituted.

Drugs covered by this patent

Patent Metadata

Patent number
EP1447405A4
Jurisdiction
EP
Classification
Expires
2005-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Kyowa Kirin Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.